Deep DiveWhen genetic medicine enters the inner earGene therapies began as proof-of-concept treatments for a handful of rare genetic disorders and now, with emerging tools, may expand into broader territories with new targeted organs. This year, one … more ➔
OutsourcingEurope rethinks the CRO-CDMO modelShould a biotech hand its molecule to a single integrated partner, or build a network of specialists around it? Manufacturers and clinical providers are answering in both directions at once: some are … more ➔
Deep DiveEurope takes cancer science into immunologyInspired by technology and insights gleaned from cancer research, Europe is leading the quest for a new generation of therapies in immunology and inflammation. Immunotherapy has revolutionised cancer … more ➔
autoimmune diseaseWhat’s next for argenx, Europe’s autoimmune breakthrough?Over the past few years, Belgium’s argenx has become a biotech force to be reckoned with, driven by the success of its autoimmune drug Vyvgart (efgartigimod alfa) in diseases such as generalised … more ➔
Venture Capital“AI biotech” is no longer a useful category for investorsAI has transformed drug discovery, but the “AI biotech” label has become increasingly misleading. Kurma Partners proposes an investment framework that distinguishes three fundamentally different … more ➔
multiple sclerosisImmunic CEO: “We want to understand MS patients better than anyone”Immunic is preparing to transition from a late-stage development biotechnology company into a fully integrated commercial organization focused on multiple sclerosis (MS). At the center of its strategy … more ➔
WatchlistSix Spanish biotech startups to watch in 2026The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: Spain counted 1,119 dedicated biotech companies in 2025, up 10.4% year on year, … more ➔
drug deliveryCell therapies: breaking barriers in solid tumoursIt’s been nearly a decade since the first CAR-T cancer cell therapy was approved by the FDA, offering a powerful and durable therapy against tumours. But when it comes to fighting solid tumours, … more ➔
EntrepreneurshipThe Strüngmann legacy, passed onThomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most famously BioNTech. Now, as a new generation takes a larger role in their family … more ➔
BioNTech SEOncologyBioNTech adds clinical weight to its oncology pivot at WCLC 2026New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously … more ➔
BioNTech SE